IFNL3Your two copies: rs12979860C/rs12979860T
CTUnfavorable response genotype
An immune gene that affects how well hepatitis C treatment works.
This result changes the label.
Example report. The whole genome example: a public genome from the 1000 Genomes Project, with CYP2D6 Structural Analysis, so you can see what yours will look like. Get your own report
Antivirals · AntiviralsExample report
Ribavirin
Copegus, Rebetol, Virazole
Consider alternative
This hepatitis C treatment is less likely to clear the virus for people with your genes. Your doctor may consider a different treatment.
The genes behind this label
The guidelines read one gene for ribavirin. Each card shows the two copies this person inherited and what they mean.
What the guidelines say
What each guideline says about your result.
IFNL3Unfavorable response genotype
CPIC guideline
Evidence: strongRead the guideline (Clinical Pharmacogenetics Implementation Consortium, opens in a new tab)
- In plain words
- This hepatitis C treatment is less likely to clear the virus for people with your genes. Your doctor may consider a different treatment.
- What it means
- Approximately 30% chance for sustained virologic response (SVR) after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens.
- What the guideline suggests
- Approximately 60% chance for SVR after 24-48 weeks of treatment. Approximately 50% of patients are eligible for shortened therapy (24-28 weeks). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.
About ribavirin
Ribavirin is an oral antiviral used for chronic hepatitis C, always in combination with other antivirals.
- Used for
- Chronic hepatitis C, always with other antivirals
Others in antivirals
Compare all 5 antiviralsDon't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.